RNC Capital Management LLC Cuts Position in Sanofi (NASDAQ:SNY)

RNC Capital Management LLC reduced its position in shares of Sanofi (NASDAQ:SNY – Get Rating) by 16.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,581 shares of the company’s stock after selling 1,310 shares during the period. RNC Capital Management LLC’s holdings in Sanofi were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SNY. MGO One Seven LLC lifted its stake in Sanofi by 5.2% during the 2nd quarter. MGO One Seven LLC now owns 4,815 shares of the company’s stock worth $241,000 after acquiring an additional 239 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Sanofi by 0.9% during the third quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock worth $996,000 after purchasing an additional 246 shares in the last quarter. Pinnacle Financial Partners Inc. boosted its stake in shares of Sanofi by 5.0% in the third quarter. Pinnacle Financial Partners Inc. now owns 5,527 shares of the company’s stock valued at $210,000 after purchasing an additional 261 shares during the period. Checchi Capital Advisers LLC grew its holdings in shares of Sanofi by 1.6% in the third quarter. Checchi Capital Advisers LLC now owns 16,520 shares of the company’s stock valued at $628,000 after purchasing an additional 261 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC grew its holdings in shares of Sanofi by 6.5% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 4,253 shares of the company’s stock valued at $162,000 after purchasing an additional 261 shares in the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Down 0.8 %

SNY opened at $47.74 on Friday. The business’s 50-day simple moving average is $47.98 and its 200-day simple moving average is $45.01. The company has a market cap of $120.38 billion, a P/E ratio of 16.87, a PEG ratio of 1.48 and a beta of 0.54. Sanofi has a one year low of $36.91 and a one year high of $58.10. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.05 and a current ratio of 1.42.

Sanofi (NASDAQ:SNY – Get Rating) last announced its quarterly earnings results on Friday, February 3rd. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Sanofi had a net margin of 15.70% and a return on equity of 28.00%. The company had revenue of $10.95 billion during the quarter, compared to analysts’ expectations of $11.51 billion. As a group, equities research analysts expect that Sanofi will post 4.4 EPS for the current fiscal year.

Sanofi Cuts Dividend

The business also recently disclosed an annual dividend, which will be paid on Friday, June 23rd. Shareholders of record on Wednesday, May 31st will be paid a $1.377 dividend. The ex-dividend date of this dividend is Tuesday, May 30th. This represents a yield of 2.94%. Sanofi’s dividend payout ratio is presently 44.52%.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent research reports. TheStreet raised shares of Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, December 2nd. The Goldman Sachs Group began coverage on Sanofi in a report on Friday, December 16th. They issued a “buy” rating for the company. Finally, Morgan Stanley restated an “overweight” rating on shares of Sanofi in a report on Tuesday, December 13th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Sanofi Profile

(Get Rating)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.